Patents by Inventor Mario LACOUTURE

Mario LACOUTURE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Compositions for Reducing Side Effects in Chemotherapeutic Treatments
    Publication number: 20220160708
    Abstract: The present invention relates to a method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects. In particular, this beneficial effect is achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 26, 2022
    Inventors: Mario LACOUTURE, Philippe ANDRES
  • Methods and compositions for reducing side effects in chemotherapeutic treatments
    Patent number: 11278548
    Abstract: A method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects, is described. In particular, the beneficial effects are achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: March 22, 2022
    Assignee: Galderma Research and Development
    Inventors: Mario Lacouture, Philippe Andres
  • METHODS AND COMPOSITIONS FOR REDUCING SIDE EFFECTS IN CHEMOTHERAPEUTIC TREATMENTS
    Publication number: 20200222396
    Abstract: A method of preventing or reducing dermatological side effects of the therapeutic agents in a subject without substantial loss in efficacy, where the therapeutic agents would otherwise have significant effects, is described. In particular, the beneficial effects are achieved by using an alpha-2 adrenergic agonist to isolate body areas from pharmacological effects of the therapeutic agents, such as a chemotherapeutic agent, and to prevent or reduce inflammatory processes.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 16, 2020
    Inventors: Mario LACOUTURE, Philippe ANDRES